1-3 of 3
Aaron Broege
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Stefano Rossetti, Aaron Broege, Joanna Sabat, Shu Wiley, Salmaan Khan, Catherine Kuzmicki, Ian MacNeil, Brian Sullivan, Lance Laing
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 367.
DOI: https://doi.org/10.1158/1538-7445.AM2021-367
Published: 01 July 2021
View article
Journal Articles

Abstract 342: Sub-group of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Salmaan Khan, Adrish Sen, Catherine Kuzmicki, Ian MacNeil, Aaron Broege, Sarah Mutka, Kelly Brass, Ky McCracken, Laura Milligan, Katja Kotke, Brian Sullivan, Lance Laing
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 342.
DOI: https://doi.org/10.1158/1538-7445.AM2021-342
Published: 01 July 2021
View article
Journal Articles

Abstract 3198: Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Stefano Rossetti, Catherine Kuzmicki, Aaron Broege, Joanna Sabat, Salmaan Khan, Ian MacNeil, Brian Sullivan, Lance Laing
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3198.
DOI: https://doi.org/10.1158/1538-7445.AM2020-3198
Published: 15 August 2020
View article